<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592839</url>
  </required_header>
  <id_info>
    <org_study_id>DR-ENJ-401</org_study_id>
    <nct_id>NCT00592839</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women</brief_title>
  <official_title>A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of SCE-B on Nocturnal Vasomotor Symptoms in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duramed Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center study to evaluate the effects of SCE-B on nocturnal vasomotor
      symptoms. Study duration will be approximately 16 weeks; this includes a 4-week screening
      period and approximately 5 scheduled clinic visits. Participants will receive one of two
      strengths of SCE-B tablets plus matching placebo or placebo only, and will have a physical
      and gynecological exams that may include transvaginal ultrasound, endometrial biopsy and a
      pap smear. Participants will be asked to wear a monitoring device for a portion of the study
      and be asked to complete a daily dairy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Average Frequency of Awakenings Due to Sleep-time Hot Flashes</measure>
    <time_frame>Baseline to End of Treatment (Week 12)</time_frame>
    <description>Change= Week 12 weekly average awakening score - Baseline weekly average awakening score for the intent-to-treat cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Individual Sleep Parameters on a Three-point Scale</measure>
    <time_frame>Baseline to End of Treatment (Week 12)</time_frame>
    <description>Change= Week 12 weekly average sleep quality score - Baseline weekly average sleep quality score for the intent-to-treat cohort. The sleep quality was derived from the subject self-assessment of sleep quality graded on a three-point scale (3=excellent, 2=good, 1=poor sleep quality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Stanford Sleepiness Scale</measure>
    <time_frame>Baseline to End of Treatment (Week 12)</time_frame>
    <description>Change= Week 12 score - Baseline Score. Daytime sleepiness was derived from the subject self-assessment how they felt at a particular time of day. Subjects rated daytime sleepiness on the 7 point Stanford Sleepiness Scale (1=most alert to 7=sleepiest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Biochemical Markers of Bone Metabolism (N-telopeptide).</measure>
    <time_frame>From baseline to End of Treatment (Week 12)</time_frame>
    <description>Change= Week 12 biochemical markers of bone metabolism (N-telopeptide) - Baseline biochemical markers of bone metabolism values for the intent-to-treat cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Biochemical Markers of Bone Metabolism (Osteocalcin)</measure>
    <time_frame>Baseline to End of Treatment (Week 12)</time_frame>
    <description>Change= Week 12 biochemical markers of bone metabolism (Osteocalcin) - Baseline biochemical markers of bone metabolism values for the intent-to-treat cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Biochemical Markers of Bone Metabolism (Sex Hormone Binding Globulin).</measure>
    <time_frame>Baseline to End of Treatment (12 weeks)</time_frame>
    <description>Change= Week 12 biochemical markers of bone metabolism (Sex Hormone Binding Globulin) - Baseline biochemical markers of bone metabolism values for the intent-to-treat cohort.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Nocturnal Vasomotor Symptoms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg SCE-B Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.625 mg SCE-B Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCE-B</intervention_name>
    <description>0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Synthetic Conjugated Estrogens, B</other_name>
    <other_name>Enjuvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for 0.3 mg and 0.625 mg tablets</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Naturally or surgically menopausal

          -  Minimum 7 daily or 50 weekly moderate-to-severe hot flashes

        Exclusion Criteria:

          -  Any contraindication to hormone therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Protocol Chair</last_name>
    <role>Study Chair</role>
    <affiliation>Duramed Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Moorestown</city>
        <state>New Jersey</state>
        <zip>08057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2008</study_first_posted>
  <results_first_submitted>February 4, 2010</results_first_submitted>
  <results_first_submitted_qc>March 5, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2010</results_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nocturnal vasomotor symptoms in postmenopausal women</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Estrogens, conjugated synthetic A</mesh_term>
    <mesh_term>Estrogens, conjugated synthetic B</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.3 mg SCE-B Daily</title>
          <description>SCE-B tablet 0.3 mg/day orally</description>
        </group>
        <group group_id="P2">
          <title>0.625 mg SCE-B Daily</title>
          <description>SCE-B tablet 0.625 mg/day orally</description>
        </group>
        <group group_id="P3">
          <title>Placebo Daily</title>
          <description>Placebo tablet daily orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.3 mg SCE-B Daily</title>
          <description>SCE-B tablet 0.3 mg/day orally</description>
        </group>
        <group group_id="B2">
          <title>0.625 mg SCE-B Daily</title>
          <description>SCE-B tablet 0.625 mg/day orally</description>
        </group>
        <group group_id="B3">
          <title>Placebo Daily</title>
          <description>Placebo tablet daily orally</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 30 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="6.00"/>
                    <measurement group_id="B2" value="54.6" spread="5.38"/>
                    <measurement group_id="B3" value="53.8" spread="6.27"/>
                    <measurement group_id="B4" value="54.1" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Average Frequency of Awakenings Due to Sleep-time Hot Flashes</title>
        <description>Change= Week 12 weekly average awakening score - Baseline weekly average awakening score for the intent-to-treat cohort</description>
        <time_frame>Baseline to End of Treatment (Week 12)</time_frame>
        <population>Participants analyzed consisted of subjects from the intent-to-treat (ITT) cohort, [all subjects who were exposed to investigational product therapy,provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit]. Not all study subjects completed all data elements in their study diaries.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.3 mg/day orally</description>
          </group>
          <group group_id="O2">
            <title>0.625 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.625 mg/day orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo Daily</title>
            <description>Placebo tablet daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Average Frequency of Awakenings Due to Sleep-time Hot Flashes</title>
          <description>Change= Week 12 weekly average awakening score - Baseline weekly average awakening score for the intent-to-treat cohort</description>
          <population>Participants analyzed consisted of subjects from the intent-to-treat (ITT) cohort, [all subjects who were exposed to investigational product therapy,provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit]. Not all study subjects completed all data elements in their study diaries.</population>
          <units>Awakenings</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.54" spread="1.195"/>
                    <measurement group_id="O2" value="-20.55" spread="1.286"/>
                    <measurement group_id="O3" value="-15.99" spread="1.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Individual Sleep Parameters on a Three-point Scale</title>
        <description>Change= Week 12 weekly average sleep quality score - Baseline weekly average sleep quality score for the intent-to-treat cohort. The sleep quality was derived from the subject self-assessment of sleep quality graded on a three-point scale (3=excellent, 2=good, 1=poor sleep quality)</description>
        <time_frame>Baseline to End of Treatment (Week 12)</time_frame>
        <population>Participants analyzed consisted of subjects from the ITT cohort, defined as all subjects who were exposed to investigational product therapy and who provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit. Not all study subjects completed all data elements in their study diaries.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.3 mg/day orally</description>
          </group>
          <group group_id="O2">
            <title>0.625 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.625 mg/day orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo Daily</title>
            <description>Placebo tablet daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Individual Sleep Parameters on a Three-point Scale</title>
          <description>Change= Week 12 weekly average sleep quality score - Baseline weekly average sleep quality score for the intent-to-treat cohort. The sleep quality was derived from the subject self-assessment of sleep quality graded on a three-point scale (3=excellent, 2=good, 1=poor sleep quality)</description>
          <population>Participants analyzed consisted of subjects from the ITT cohort, defined as all subjects who were exposed to investigational product therapy and who provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit. Not all study subjects completed all data elements in their study diaries.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.066"/>
                    <measurement group_id="O2" value="0.56" spread="0.068"/>
                    <measurement group_id="O3" value="0.47" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Stanford Sleepiness Scale</title>
        <description>Change= Week 12 score - Baseline Score. Daytime sleepiness was derived from the subject self-assessment how they felt at a particular time of day. Subjects rated daytime sleepiness on the 7 point Stanford Sleepiness Scale (1=most alert to 7=sleepiest).</description>
        <time_frame>Baseline to End of Treatment (Week 12)</time_frame>
        <population>Participants analyzed consisted of subjects from the ITT cohort, defined as all subjects who were exposed to investigational product therapy and who provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit. Not all study subjects completed all data elements in their study diaries.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.3 mg/day orally</description>
          </group>
          <group group_id="O2">
            <title>0.625 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.625 mg/day orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo Daily</title>
            <description>Placebo tablet daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Stanford Sleepiness Scale</title>
          <description>Change= Week 12 score - Baseline Score. Daytime sleepiness was derived from the subject self-assessment how they felt at a particular time of day. Subjects rated daytime sleepiness on the 7 point Stanford Sleepiness Scale (1=most alert to 7=sleepiest).</description>
          <population>Participants analyzed consisted of subjects from the ITT cohort, defined as all subjects who were exposed to investigational product therapy and who provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit. Not all study subjects completed all data elements in their study diaries.</population>
          <units>Score on Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.117"/>
                    <measurement group_id="O2" value="-0.44" spread="0.117"/>
                    <measurement group_id="O3" value="-0.62" spread="0.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Biochemical Markers of Bone Metabolism (N-telopeptide).</title>
        <description>Change= Week 12 biochemical markers of bone metabolism (N-telopeptide) - Baseline biochemical markers of bone metabolism values for the intent-to-treat cohort.</description>
        <time_frame>From baseline to End of Treatment (Week 12)</time_frame>
        <population>Participants analyzed consisted of subjects from the ITT cohort, defined as all subjects who were exposed to investigational product therapy and who provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit. Not all study subjects completed all data elements in their study diaries.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.3 mg/day orally</description>
          </group>
          <group group_id="O2">
            <title>0.625 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.625 mg/day orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo Daily</title>
            <description>Placebo tablet daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Biochemical Markers of Bone Metabolism (N-telopeptide).</title>
          <description>Change= Week 12 biochemical markers of bone metabolism (N-telopeptide) - Baseline biochemical markers of bone metabolism values for the intent-to-treat cohort.</description>
          <population>Participants analyzed consisted of subjects from the ITT cohort, defined as all subjects who were exposed to investigational product therapy and who provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit. Not all study subjects completed all data elements in their study diaries.</population>
          <units>nM BCE</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="6.67"/>
                    <measurement group_id="O2" value="-3.8" spread="5.37"/>
                    <measurement group_id="O3" value="-0.6" spread="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Biochemical Markers of Bone Metabolism (Osteocalcin)</title>
        <description>Change= Week 12 biochemical markers of bone metabolism (Osteocalcin) - Baseline biochemical markers of bone metabolism values for the intent-to-treat cohort.</description>
        <time_frame>Baseline to End of Treatment (Week 12)</time_frame>
        <population>Participants analyzed consisted of subjects from the ITT cohort, defined as all subjects who were exposed to investigational product therapy and who provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit. Not all study subjects completed all data elements in their study diaries.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.3 mg/day orally</description>
          </group>
          <group group_id="O2">
            <title>0.625 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.625 mg/day orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo Daily</title>
            <description>Placebo tablet daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Biochemical Markers of Bone Metabolism (Osteocalcin)</title>
          <description>Change= Week 12 biochemical markers of bone metabolism (Osteocalcin) - Baseline biochemical markers of bone metabolism values for the intent-to-treat cohort.</description>
          <population>Participants analyzed consisted of subjects from the ITT cohort, defined as all subjects who were exposed to investigational product therapy and who provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit. Not all study subjects completed all data elements in their study diaries.</population>
          <units>ng*ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="7.29"/>
                    <measurement group_id="O2" value="-4.4" spread="7.94"/>
                    <measurement group_id="O3" value="-0.3" spread="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Biochemical Markers of Bone Metabolism (Sex Hormone Binding Globulin).</title>
        <description>Change= Week 12 biochemical markers of bone metabolism (Sex Hormone Binding Globulin) - Baseline biochemical markers of bone metabolism values for the intent-to-treat cohort.</description>
        <time_frame>Baseline to End of Treatment (12 weeks)</time_frame>
        <population>Participants analyzed consisted of subjects from the ITT cohort, defined as all subjects who were exposed to investigational product therapy and who provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit. Not all study subjects completed all data elements in their study diaries.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.3 mg/day orally</description>
          </group>
          <group group_id="O2">
            <title>0.625 mg SCE-B Daily</title>
            <description>SCE-B tablet 0.625 mg/day orally</description>
          </group>
          <group group_id="O3">
            <title>Placebo Daily</title>
            <description>Placebo tablet daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Biochemical Markers of Bone Metabolism (Sex Hormone Binding Globulin).</title>
          <description>Change= Week 12 biochemical markers of bone metabolism (Sex Hormone Binding Globulin) - Baseline biochemical markers of bone metabolism values for the intent-to-treat cohort.</description>
          <population>Participants analyzed consisted of subjects from the ITT cohort, defined as all subjects who were exposed to investigational product therapy and who provided baseline &quot;sleep time&quot; hot flash information and &quot;sleep time&quot; hot flash data for at least one post-baseline visit. Not all study subjects completed all data elements in their study diaries.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="21.05"/>
                    <measurement group_id="O2" value="44.8" spread="38.86"/>
                    <measurement group_id="O3" value="-3.3" spread="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event reporting began on the first day of signing the informed consent and ended at the end of study drug treatment (approximately 16 weeks).</time_frame>
      <desc>Adverse events were reported during the subject's regularly scheduled visits at the investigational site.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.3 mg SCE-B Daily</title>
          <description>SCE-B tablet 0.3 mg/day orally</description>
        </group>
        <group group_id="E2">
          <title>0.625 mg SCE-B Daily</title>
          <description>SCE-B tablet 0.625 mg/day orally</description>
        </group>
        <group group_id="E3">
          <title>Placebo Daily</title>
          <description>Placebo tablet daily orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right tibia and fibula shaft fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Naspoharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can (i) review results communications prior to public release and can embargo communications regarding trial results for a period of at least 60 days but no more than 180 days from the time submitted to the sponsor for review; and (ii) require in instances of a multi-center study, that a single PI not disclose study data until after the multi-center results are published, provided such results are published within eighteen (18) months of the conclusion of the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Duramed Research Protocol Chair</name_or_title>
      <organization>Duramed Research</organization>
      <phone>215-293-7279</phone>
      <email>medicalaffairs@barrlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

